Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Colorcon
Dow
Baxter
AstraZeneca

Last Updated: May 26, 2022

QUZYTTIR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Quzyttir patents expire, and what generic alternatives are available?

Quzyttir is a drug marketed by JDP and is included in one NDA. There are five patents protecting this drug.

This drug has five patent family members in five countries.

The generic ingredient in QUZYTTIR is cetirizine hydrochloride. There are thirty-nine drug master file entries for this compound. One hundred and thirty-five suppliers are listed for this compound. Additional details are available on the cetirizine hydrochloride profile page.

Summary for QUZYTTIR
International Patents:5
US Patents:5
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 2
Formulation / Manufacturing:see details
Drug Prices: Drug price information for QUZYTTIR
What excipients (inactive ingredients) are in QUZYTTIR?QUZYTTIR excipients list
DailyMed Link:QUZYTTIR at DailyMed
Drug patent expirations by year for QUZYTTIR
Drug Prices for QUZYTTIR

See drug prices for QUZYTTIR

Recent Clinical Trials for QUZYTTIR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
TerSera TherapeuticsPhase 2
TerSera Therapeutics LLCPhase 2
JDP Therapeutics, Inc.Phase 2

See all QUZYTTIR clinical trials

US Patents and Regulatory Information for QUZYTTIR

QUZYTTIR is protected by five US patents and one FDA Regulatory Exclusivity.

Patents protecting QUZYTTIR

Non-sedating antihistamine injection formulations and methods of use thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF ACUTE URTICARIA

Non-sedating antihistamine injection formulations and methods of use thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATMENT IN PATIENTS WITH CONCOMITANT ANGIOEDEMA

Non-sedating antihistamine injection formulations and methods of use thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF INCREASING PEAK PLASMA OR ONSET OF PLASMA CONCENTRATION BY INTRAVENOUS INJECTION IN INDIVIDUALS IN NEED OF TREATMENT FOR ACUTE URTICARIA

Non-sedating antihistamine injection formulations and methods of use thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF ACUTE URTICARIA

Non-sedating antihistamine injection formulations and methods of use thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF ACUTE URTICARIA

FDA Regulatory Exclusivity protecting QUZYTTIR

NEW PRODUCT
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Jdp QUZYTTIR cetirizine hydrochloride SOLUTION;INTRAVENOUS 211415-001 Oct 4, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Jdp QUZYTTIR cetirizine hydrochloride SOLUTION;INTRAVENOUS 211415-001 Oct 4, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Jdp QUZYTTIR cetirizine hydrochloride SOLUTION;INTRAVENOUS 211415-001 Oct 4, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for QUZYTTIR

See the table below for patents covering QUZYTTIR around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 2477634 FORMULATIONS POUR INJECTION D'UN ANTIHISTAMINIQUE NON SÉDATIF ET LEURS MÉTHODES D'UTILISATION (NON-SEDATING ANTIHISTAMINE INJECTION FORMULATIONS AND METHODS OF USE THEREOF) See Plans and Pricing
Australia 2010266103 Non-sedating antihistamine injection formulations and methods of use thereof See Plans and Pricing
Canada 2803987 FORMULATIONS POUR INJECTION D'UN ANTIHISTAMINIQUE NON SEDATIF ET LEURS METHODES D'UTILISATION (NON-SEDATING ANTIHISTAMINE INJECTION FORMULATIONS AND METHODS OF USE THEREOF) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for QUZYTTIR

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0058146 2001C/045 Belgium See Plans and Pricing PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103
0663828 C300085 Netherlands See Plans and Pricing PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Dow
Merck
McKinsey
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.